Update date
22 Jul 2026
ORAMED PHARMACEUTICALS INC. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q2 2026.
- Public ticker
- ORMP on Nasdaq
- Latest financial report
- 19 May 2026
- Company location
- New York, NY
- Fiscal year end
- 31 December
Company
Names, identifiers, and filing context for this profile.
1 identity field
SEC filing record 1 source field available
Shareable Research Card
ORMP - ORAMED PHARMACEUTICALS INC. Financial Facts
ORMP - ORAMED PHARMACEUTICALS INC. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q2 2026
- Latest reported value
- Return On Equity 58%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2026.
- Most recent SEC facts end date on this page: 19 May 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for ORMP - ORAMED PHARMACEUTICALS INC.
Latest Schedule 13D/G period: 20 Jul 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Filer profile
Latest period
Q2 2026
Schedule 13D/G context is visible from filings filed on 22 Jul 2026.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 506% versus the comparable prior period.
Compared with
Compared with ORAMED PHARMACEUTICALS INC.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- ORMP - ORAMED PHARMACEUTICALS INC. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q2 2026.
- Headline metric: Return On Equity 58%.
Change
- Return On Equity YoY change: -506%.
- Most recent SEC facts end date: 19 May 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2026-05-19) highlights Return On Equity 58.2%, Return On Assets -4.3%, and Operating Margin 0.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-210%
fair value gap
Fair value per share
$5.02
Market price
$4.57
ORMP - Local security
PEG ratio
0.0x
P/E 4.2x / growth 106%
EPS CAGR (3Y)
Enterprise value
$124.55M
Equity value
$210.89M
DCF fair value scenarios
Bear
$4.27
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -193%
Base
$5.02
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -210%
Bull
$6.21
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -236%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
139.1x
Local security market EV / SEC revenue
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Ebitda is unavailable or not positive
P/E
4.2x
Local security market price / SEC EPS
P/S
95.9x
Local security market cap / SEC revenue
P/B
0.8x
Local security market cap / SEC equity
PEG
0.0x
P/E / EPS CAGR
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $8.55M
- Trailing SEC FCF
- Reported FCF
- $8.55M
- Net income
- $46.03M
- EBITDA
- $14.13M
- Cash
- $13.2M
- Debt
- $99.55M
- Equity
- $238.28M
- Shares
- 41,970,186
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Dcf uses fallback growth assumption because historical free cash flow growth is unavailable
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
51.1/100
Caution Confidence medium
Return On Equity
58%
Metric score 100.0/100
Return On Assets
-4.3%
Metric score 0.0/100
Financial Health
- Current Ratio
- 6.45x
- Quick Ratio
- 6.28x
- Debt to Equity
- 0x
Strengths
Return On Equity and Debt-to-equity
Watchpoints
Return On Assets, Operating Margin, and Current Ratio
Key metrics snapshot
Return On Equity
58%
YoY: -506%
Return On Assets
-4.3%
YoY: -522%
Operating Margin
0%
YoY:
Current Ratio
6.45x
YoY: -73%
Quick Ratio
6.28x
YoY:
Debt-to-equity
0x
YoY:
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | 58% | -506% |
| Return On Assets | -4.3% | -522% |
| Operating Margin | 0% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 6.45x | -73% |
| Quick Ratio | 6.28x | |
| Debt-to-equity | 0x |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 40,926,081 | -0.19% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first